connecting the dots between discovery, development, and mab manufacturing efficiency
Published 2 years ago • 12 plays • Length 6:25Download video MP4
Download video MP3
Similar videos
-
8:13
what’s holding back mab manufacturing efficiencies?
-
10:43
why efficiency matters in mab manufacturing
-
44:52
connecting the dots in early drug discovery at novartis
-
38:37
mab manufacturing with rezolute bio's nevan charles elam, jd
-
2:18
the model-informed drug discovery and development program
-
1:01:48
why pharmaceuticals are so complicated in the u.s. | cnbc marathon
-
17:13
chronic lymphocytic leukemia treatment & side effects (venetoclax & obinutuzumab) | tamsin (3 of 3)
-
3:57
monoclonal antibodies | health | biology | fuseschool
-
2:10
connecting the dots | one path from drug discovery to delivery
-
4:47
pat in multi-specific antibody manufacturing
-
1:48
connecting the dots season 2 - trailer
-
35:06
accelerating mab drug development to meet increase in recent mab fda approvals
-
48:18
antibody discovery platforms to support functional monoclonal antibody generation
-
23:00
john desjarlais: "optimization and application of fc-containing bispecific antibodies"
-
7:49
introducing new technology to a multi-specific antibody line
-
49:55
drug discovery: capital and time
-
4:13
concept life sciences drug discovery & development virtual tour
-
1:11:37
scientific evaluation and due diligence of innovative monoclonal antibody therapeutics
-
3:32
monoclonal antibodies and its production
-
1:00:48
mdc connects: hit identification
-
58:58
mdc connects: structural approaches for drug discovery
-
56:47
james bradner: "small molecule therapeutics" (11/24/2020)